Authors: | Bartsch, Tabea Becker, Martin Rolf, Jascha Rosenthal, Katrin Lütz, Stephan |
Title: | Biotechnological production of cyclic dinucleotides - challenges and opportunities |
Language (ISO): | en |
Abstract: | Cyclic dinucleotides (CDNs) are widely used secondary signaling molecules in prokaryotic and eukaryotic cells. As strong agonists of the stimulator of interferon genes, they are of great interest for pharmaceutical applications. In particular, cyclic-GMP-AMP and related synthetic CDNs are promising candidates in preclinical work and even some in clinical phase 1 and 2 studies. The comparison of chemical and biocatalytic synthesis routes elucidated that biological CDN synthesis offers some advantages, such as shorter synthesis time, avoiding complex protective group chemistry, and the access to a new spectrum of CDNs. However, the synthesis of CDNs in preparative quantities is still a challenge, since the chemical synthesis of CDNs suffers from low yields and complex synthetic routes and the enzymatically catalyzed synthesis is limited by low product titers and process stability. We aim to review the latest discoveries and recent trends in chemical and biocatalytic synthesis of CDNs with a focus on the synthesis of a huge variety of CDN derivatives. We furthermore consider the most promising biotechnological processes for CDN production by evaluating key figures of the currently known processes. |
Subject Headings: | c-di-GMP cGAMP cGAS Cyclic dinucleotide (CDN) DncV Nucleotidyltransferase |
URI: | http://hdl.handle.net/2003/40760 http://dx.doi.org/10.17877/DE290R-22618 |
Issue Date: | 2021-12-25 |
Rights link: | https://creativecommons.org/licenses/by/4.0/ |
Appears in Collections: | Arbeitsgruppe Bioverfahrenstechnik |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Biotech Bioengineering - 2021 - Bartsch - Biotechnological production of cyclic dinucleotides Challenges and.pdf | 1.08 MB | Adobe PDF | View/Open |
This item is protected by original copyright |
This item is licensed under a Creative Commons License